Optimal Sequencing of Therapy for Previously Treated Patients With Relapsed or Refractory ALL
February 16th 2024
Dr. Shah and colleagues dissect the social determinants of health, including limited personal resources, frailty, distance to treatment facilities, therapeutic compliance, and other considerations that impact effective treatment sequencing for patients with relapsed or refractory ALL, including access to care and CAR-T cell availability.